

# Accepted Manuscript

Brain Metastases (BM) in Pancreatic Ductal Adenocarcinoma (PDAC): Assessment of molecular genotype-phenotype features. An Entity with an Increasing Incidence?

Emmet J. Jordan, Maeve A. Lowery, Olca Basturk, Peter J. Allen, Kenneth H. Yu, Viviane Tabar, Kathryn Beal, Diane L. Reidy, Yoshiya Yamada, Yelena Janjigian, Ghassan K. Abou-Alfa, Eileen M. O'Reilly

PII: S1533-0028(17)30290-6

DOI: [10.1016/j.clcc.2018.01.009](https://doi.org/10.1016/j.clcc.2018.01.009)

Reference: CLCC 431

To appear in: *Clinical Colorectal Cancer*


Received Date: 26 July 2017

Revised Date: 21 January 2018

Accepted Date: 31 January 2018

Please cite this article as: Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM, Brain Metastases (BM) in Pancreatic Ductal Adenocarcinoma (PDAC): Assessment of molecular genotype-phenotype features. An Entity with an Increasing Incidence?, *Clinical Colorectal Cancer* (2018), doi: 10.1016/j.clcc.2018.01.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Brain Metastases (BM) in Pancreatic Ductal Adenocarcinoma (PDAC): Assessment of molecular genotype-phenotype features. An Entity with an Increasing Incidence?**

Emmet J. Jordan<sup>1</sup>, Maeve A. Lowery<sup>1,3,4</sup>, Olca Basturk<sup>2</sup>, Peter J. Allen<sup>5</sup>, Kenneth H. Yu<sup>1,4</sup>, Viviane Tabar<sup>7</sup>, Kathryn Beal<sup>6</sup>, Diane L. Reidy<sup>1</sup>, Yoshiya Yamada<sup>6</sup>, Yelena Janjigian<sup>1</sup>, Ghassan K. Abou-Alfa<sup>1,4</sup>, Eileen M. O'Reilly<sup>1,3,4</sup>

1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3. The David Rubenstein Pancreatic Cancer Research Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4. Weill Cornell Medical College, New York, NY, USA
5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7. Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Corresponding Author:**

**Eileen O' Reilly, M.D.**

Gastrointestinal Oncology Service, Department of Medicine,  
Memorial Sloan Kettering Cancer Center,  
300 East 66<sup>th</sup> Street, Office 1021  
New York, NY, 10065  
Tel: 646 888-4182  
Fax: 646 888-4542  
Email: oreillye@mskcc.org

**Conflict of Interest:** The authors have no potential conflict of interest.

Download English Version:

<https://daneshyari.com/en/article/8613075>

Download Persian Version:

<https://daneshyari.com/article/8613075>

[Daneshyari.com](https://daneshyari.com)